Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.0K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.0K
RNA Editing02:23

RNA Editing

9.9K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.9K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

207
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
207
RNA Interference01:23

RNA Interference

28.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.2K
RNA Structure01:23

RNA Structure

79.2K
Overview
The basic structure of RNA consists of a five-carbon sugar and one of four nitrogenous bases. Although most RNA is single-stranded, it can form complex secondary and tertiary structures. Such structures play essential roles in the regulation of transcription and translation.
Different Types of RNA Have the Same Basic Structure
There are three main types of ribonucleic acid (RNA): messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). All three RNA types consist of a...
79.2K
RNA Stability01:53

RNA Stability

35.8K
Intact DNA strands can be found in fossils, while scientists sometimes struggle to keep RNA intact under laboratory conditions. The structural variations between RNA and DNA underlie the differences in their stability and longevity. Because DNA is double-stranded, it is inherently more stable. The single-stranded structure of RNA is less stable but also more flexible and can form weak internal bonds. Additionally, most RNAs in the cell are relatively short, while DNA can be up to 250 million...
35.8K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Cyclic nucleotide phosphodiesterases as drug targets.

Pharmacological reviews·2025
Same author

Age-associated temporal decline in butyrate-producing bacteria plays a key pathogenic role in the onset and progression of neuropathology and memory deficits in 3×Tg-AD mice.

Gut microbes·2024
Same author

Back to phosphodiesterase inhibitors for liver disease: Are we ready for clinical trials?

Hepatology (Baltimore, Md.)·2024
Same author

Association of Circulating Markers of Microbial Translocation and Hepatic Inflammation with Liver Injury in Patients with Type 2 Diabetes.

Biomedicines·2024
Same author

Hepatocyte-specific mitogen-activated protein kinase phosphatase 1 in sexual dimorphism and susceptibility to alcohol induced liver injury.

Frontiers in immunology·2024
Same author

GPR65 as a potential novel therapeutic target for the treatment of hepatic fibrosis.

Military Medical Research·2024

Video Experimental Relacionado

Updated: Feb 9, 2026

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data
07:35

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data

Published on: December 1, 2023

1.2K

ARN largo no codificante H19 en el desarrollo y las enfermedades del hígado

Diego Elias Montoya-Durango1, Leila Gobejishvili1

  • 1Department of Physiology, University of Louisville School of Medicine, Louisville, KY 40202, United States of America; Alcohol Research Center, University of Louisville School of Medicine, Louisville, KY 40202, United States of America.

Cellular signalling
|February 7, 2026
PubMed
Resumen

El gen de ARN largo no codificante H19 es crucial en el desarrollo y las enfermedades del hígado. Su reexpresión en hígados adultos promueve el hígado graso, la fibrosis y el cáncer, destacando su potencial terapéutico.

Palabras clave:
FibrosisMetabolismo lipídicoHígadoCáncer de hígadoLesión hepáticaARN largo no codificante H19

Más Videos Relacionados

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.3K
Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

4.0K

Videos de Experimentos Relacionados

Last Updated: Feb 9, 2026

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data
07:35

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data

Published on: December 1, 2023

1.2K
Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.3K
Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

4.0K

Área de la Ciencia:

  • Biología Molecular
  • Hepatología
  • Genética

Sus antecedentes:

  • La enfermedad hepática causa más de 2 millones de muertes anuales, siendo la EH y la EHA contribuyentes importantes.
  • La dieta y el alcohol impulsan patologías hepáticas como la esteatosis, la fibrosis, la cirrosis y el carcinoma hepatocelular.
  • Se necesitan urgentemente terapias novedosas debido a las limitadas opciones de tratamiento para el daño hepático.

Objetivo del estudio:

  • Revisar los multifacéticos roles del gen H19 en el desarrollo del hígado.
  • Resumir la participación de H19 en enfermedades hepáticas, incluyendo el hígado graso, la fibrosis y el carcinoma hepatocelular.
  • Explorar las funciones reguladoras de H19 en el metabolismo, la fibrosis, el ciclo celular y la cromatina.

Principales métodos:

  • Revisión de literatura de estudios sobre la función del gen H19 en el desarrollo y las enfermedades del hígado.
  • Análisis de las interacciones de H19 con proteínas, ARN codificantes y ARN no codificantes.
  • Resumen de la regulación epigenética de H19 y su impacto en las patologías hepáticas.

Principales resultados:

  • H19 es esencial para el desarrollo embrionario y la maduración del hígado neonatal.
  • La reexpresión de H19 en hígados adultos impulsa la lipogénesis, la fibrosis y mantiene la proliferación de las células tumorales.
  • H19 interactúa con numerosas moléculas que regulan el metabolismo, la fibrosis, el ciclo celular y la cromatina.

Conclusiones:

  • H19 desempeña un doble papel, crítico para el desarrollo del hígado pero patógeno en la enfermedad hepática adulta.
  • Comprender las complejas funciones de H19 es clave para desarrollar nuevas estrategias terapéuticas para las enfermedades hepáticas.
  • La focalización de H19 puede ofrecer un enfoque novedoso para tratar la enfermedad del hígado graso asociada a disfunción metabólica y el carcinoma hepatocelular.